Evolus (EOLS) Change in Accured Expenses (2017 - 2026)
Evolus' (EOLS) quarterly Change in Accured Expenses came in at -$3.7 million in Q1 2026, up 73.58% YoY from -$2.2 million in Q1 2025, and down 194.69% on a QoQ basis from $4.0 million in Q4 2025.
Evolus (EOLS) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Change in Accured Expenses data on file, last reported at -$3.7 million in Q1 2026.
- Quarterly Change in Accured Expenses rose 73.58% year-over-year to -$3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 141.9% YoY) and the FY2025 annual result came in at -$6.4 million, down 191.2% from the prior year.
- Change in Accured Expenses declined to -$3.7 million in Q1 2026, from $4.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $7.9 million in Q2 2024 to a low of -$14.2 million in Q1 2025.
- A 5-year average of $40588.2 and a median of $2.1 million in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 355.53% — and 2024, when it surged 278.36%.
- Tracing EOLS's Change in Accured Expenses over 5 years: stood at -$5.1 million in 2022, then soared by 239.52% to $7.1 million in 2023, then decreased by 17.73% to $5.8 million in 2024, then plunged by 32.31% to $4.0 million in 2025, then tumbled by 194.69% to -$3.7 million in 2026.
- The last three Change in Accured Expenses figures came in at -$3.7 million (Q1 2026), $4.0 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Evolus | 550.51 Mn | 505.34 Mn | 57.18 Mn | 6.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.24 Mn |
| Jun 30, 2026 | 6.24 Mn |
| Mar 31, 2026 | -3.74 Mn |
| Mar 31, 2026 | -3.74 Mn |
| Dec 31, 2025 | 3.95 Mn |
| Dec 31, 2025 | 3.95 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | -14.17 Mn |
| Mar 31, 2025 | -14.17 Mn |
| Dec 31, 2024 | 5.84 Mn |
| Dec 31, 2024 | 5.84 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 7.85 Mn |
| Jun 30, 2024 | 7.85 Mn |
| Mar 31, 2024 | -8.87 Mn |
| Mar 31, 2024 | -8.87 Mn |